Sprycel (dasatinib) is a small molecule pharmaceutical. Dasatinib was first approved as Sprycel on 2006-06-28. It is used to treat lymphoid leukemia and myeloid leukemia in the USA. It has been approved in Europe to treat bcr-abl positive chronic myelogenous leukemia and precursor cell lymphoblastic leukemia-lymphoma. The pharmaceutical is active against tyrosine-protein kinase ABL1. In addition, it is known to target proto-oncogene tyrosine-protein kinase Src, probable serine/threonine-protein kinase SIK1B, serine/threonine-protein kinase SIK2, and serine/threonine-protein kinase SIK3. Sprycel's patent is valid until 2026-03-28 (FDA).
|Indication||bcr-abl positive chronic myelogenous leukemia, lymphoid leukemia, myeloid leukemia, precursor cell lymphoblastic leukemia-lymphoma|
|Drug Class||Tyrosine kinase inhibitors|